Bullish for Dabur, Emami: Karnataka HC Stays FSSAI Ashwagandha Ban

The Karnataka High Court has temporarily stayed an advisory from the Food Safety and Standards Authority of India (FSSAI) that restricted the use of Ashwagandha leaves and their extracts in dietary and health products. This provides relief to eight firms, including US-based Kerry Inc.

This stay is significant for the Indian nutraceutical and ayurvedic industry, where Ashwagandha is a widely used ingredient. The FSSAI advisory had created uncertainty and potential operational challenges for companies. The temporary relief allows these firms to continue using Ashwagandha, preventing disruption to their product lines and sales.

This is positive for Indian FMCG and pharmaceutical companies with a strong presence in health supplements and ayurvedic products that utilize Ashwagandha, such as DABUR, EMAMILTD, and Himalaya Wellness (though not listed, it's a key player). It removes a regulatory overhang, potentially supporting their product portfolios and revenue streams.

Traders should monitor the ongoing legal proceedings and await a final decision from the Karnataka High Court or any revised guidelines from FSSAI. The long-term impact will depend on the permanent resolution of this regulatory issue. Also, observe any new product launches or marketing campaigns by companies leveraging Ashwagandha.

• •Karnataka HC stays FSSAI advisory on use of Ashwagandha leaves.
• •Relief granted to Kerry Inc and 7 other firms.
• •FSSAI had previously barred Ashwagandha leaves and extracts in dietary products.
• •Risk flag: Final court decision reversing the stay
• •Risk flag: New FSSAI regulations with different restrictions